| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_40a92325286ca98dbffa06d2c67ed064 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D215-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-12 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D215-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-12 |
| filingDate |
1998-06-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
1999-10-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5231229d3ba1a2a4b3ff2ee907c51dd6 |
| publicationDate |
1999-10-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-5972945-A |
| titleOfInvention |
2-aminoalkylaminoquinolines; dopamine receptor subtype specific ligands |
| abstract |
Disclosed are compounds of the formula: or the pharmaceutically acceptable salts thereof wherein: R1, R2, and R3 are as defined herein; R6 is hydrogen or C1-C6 alkyl, and Q represents a substituted azacycloalkylalkyl group, which compounds are useful in treating psychotic disorders such as schizophrenia and other central nervous system diseases. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6706699-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7009054-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6313141-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2004152671-A1 |
| priorityDate |
1997-06-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |